Ultrasonix Medical Corp. has announced it has received FDA approval for its SonixGPS needle guidance technology for vascular access procedures, according to a news release.
The SonixGPS technology is used for guidance procedures such as nerve blocks for regional anesthesia and pain management and vascular access procedures.
The guidance technology is also intended for use for biopsies, aspirations and placement of therapeutic agents.
"Our SonixGPS technology exemplifies our company's focus on innovation, guidance and simplicity," said Laurent Pelissier, founder and CEO of Ultrasonix, in the release. "We are delighted to have regulatory approvals in key global areas. We believe our guidance technology can improve patient safety and save physicians valuable time. We look forward to expanding its footprint."
SonixGPS for nerve block procedures is pending FDA clearance.
Ultrasonix Medical Corp. is headquartered in British Columbia, Canada.
Related Articles on FDA Clearances:
FDA Approves First Glaucoma Stent for Cataract Surgery
Cardinal Health Receives New FDA Clearance for Durablue Sterilization Wrap
InTouch Health Receives FDA 510(k) Clearance for Remote Presence Devices